Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Juvenile Macular Degeneration (Stargardt Disease) - Overview
Juvenile Macular Degeneration (Stargardt Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Juvenile Macular Degeneration (Stargardt Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Juvenile Macular Degeneration (Stargardt Disease) - Companies Involved in Therapeutics Development
4P-Pharma SAS
Alkeus Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Alpine Biotherapeutics Corp
Applied Genetic Technologies Corp
Astellas Pharma Inc
Beam Therapeutics Inc
Belite Bio Inc
Biophytis SA
Brooklyn ImmunoTherapeutics Inc
Cardax Inc
Coave Therapeutics
Copernicus Therapeutics Inc
Curative Biotechnology Inc
Fera Pharmaceuticals LLC
Generation Bio Co
Grupo Ferrer Interciol SA
IVERIC bio Inc
jCyte Inc
Katairo GmbH
Kubota Vision Inc
Lysoclear Inc
Mediphage Bioceuticals Inc
noscope Therapeutics Inc
Oak bay Biosciences Ltd
ProQR Therapeutics NV
Ray Therapeutics Inc
ReVision Therapeutics Inc
Saliogen Therapeutics Inc
Shape Therapeutics Inc
Spark Therapeutics Inc
Splice Bio SL
Stargazer Pharmaceuticals Inc
Juvenile Macular Degeneration (Stargardt Disease) - Drug Profiles
4P-020 - Drug Profile
Product Description
Mechanism Of Action
ALK-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Aptamer to Inhibit CFD for Juvenile Macular Degeneration (Stargardt Disease) - Drug Profile
Product Description
Mechanism Of Action
ASP-7317 - Drug Profile
Product Description
Mechanism Of Action
History of Events
avacincaptad pegol sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
BIO-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CDX-301 - Drug Profile
Product Description
Mechanism Of Action
CTxABCA-4 - Drug Profile
Product Description
Mechanism Of Action
ecothiopate iodide - Drug Profile
Product Description
Mechanism Of Action
History of Events
emixustat hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
FAB-111 - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy 1 to Activate ABCA4 for Stargardt Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene therapy for Juvenile Macular Degeneration (Stargardt Disease) - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate ABCA4 for Stargardt Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate ABCA4 for Stargardt Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate ABCA4 for Stargardt Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate ABCA4 for Stargardt Disease - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy To Activate ABCA4 for Stargardt Disease - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy to Activate ABCA4 for Stargardt Disease - Drug Profile
Product Description
Mechanism Of Action
GTSG - Drug Profile
Product Description
Mechanism Of Action
Jcell - Drug Profile
Product Description
Mechanism Of Action
History of Events
Lead program in Stargardt disease - Drug Profile
Product Description
Mechanism Of Action
metformin - Drug Profile
Product Description
Mechanism Of Action
History of Events
miniABCA4: STGD1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
QR-1011 - Drug Profile
Product Description
Mechanism Of Action
RAY-001 - Drug Profile
Product Description
Mechanism Of Action
Recombint Enzyme for Age Related Macular Degeneration and Stargardt Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
REV-0100 - Drug Profile
Product Description
Mechanism Of Action
History of Events
SHP-261 - Drug Profile
Product Description
Mechanism Of Action
soraprazan - Drug Profile
Product Description
Mechanism Of Action
History of Events
Stargardt - Drug Profile
Product Description
Mechanism Of Action
Stargardt Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
Stem Cell Therapy for Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
History of Events
STG-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TFB for Dry Age-Related Macular Degeneration, Stargardt Macular Dystrophy - Drug Profile
Product Description
Mechanism Of Action
tinlarebant - Drug Profile
Product Description
Mechanism Of Action
History of Events
VMCO-1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
vutrisiran - Drug Profile
Product Description
Mechanism Of Action
History of Events
Juvenile Macular Degeneration (Stargardt Disease) - Dormant Projects
Juvenile Macular Degeneration (Stargardt Disease) - Product Development Milestones
Featured News & Press Releases
Apr 12, 2022: Fera Pharmaceuticals announces FDA Orphan Desigtion of Phospholine Iodide for the treatment of Stargardt disease
Jan 25, 2022: noscope Therapeutics announces FDA clearance of IND for MCO-010 gene therapy in Stargardt macular degeneration patients
Jan 10, 2022: noscope awarded key U.S. patent protecting its multi-characteristic Opsin Gene Therapy platform for reversing blindness
Aug 25, 2021: Aequus strengthens clinical experience in Stargardt disease with pediatric ophthalmology expertise
Jul 14, 2021: FDA grants Alkeus Pharmaceuticals Breakthrough Therapy desigtion for ALK-001 (C20-D3-vitamin A) for the treatment of Stargardt Disease
Jun 30, 2021: Belite Bio announces start of LBS-008 phase 3 Stargardt Disease trial
Mar 03, 2021: noscope president to deliver talk on gene therapy for retil diseases at Association for Ocular Pharmacology and Therapeutics conference
Jan 25, 2021: noscope Therapeutics receives Orphan Drug Desigtion for gene therapy of blindness
Nov 24, 2020: Kubota Vision announces publication of Emixustat?s pharmacodymic effects in patients with stargardt disease
Oct 28, 2020: reVision Therapeutics announces US FDA Grant of rare pediatric disease and orphan-drug desigtion for REV-0100 for the treatment of Stargardt disease
Aug 20, 2020: Kubota Vision receives orphan products clinical trials grants to Emixustat for stargardt disease
Jul 20, 2020: Belite Bio announces positive results from phase 1 clinical trials of LBS-008
May 01, 2020: Kubota Vision completes enrollment in the Emixustat phase 3 clinical trial in patients with Stargardt disease
Feb 13, 2020: Acucela provides update on Emixustat phase 3 clinical trial in patients with Stargardt disease
Jan 06, 2020: Acucela announces publication assessing the role of Emixustat Hydrochloride in retil degeneration treatment
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by 4P-Pharma SAS, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Alkeus Pharmaceuticals Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Alnylam Pharmaceuticals Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Alpine Biotherapeutics Corp, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Applied Genetic Technologies Corp, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Astellas Pharma Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Beam Therapeutics Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Belite Bio Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Biophytis SA, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Brooklyn ImmunoTherapeutics Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Cardax Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Coave Therapeutics, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Copernicus Therapeutics Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Curative Biotechnology Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Fera Pharmaceuticals LLC, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Generation Bio Co, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Grupo Ferrer Internacional SA, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by IVERIC bio Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by jCyte Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Katairo GmbH, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Kubota Vision Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Lysoclear Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Mediphage Bioceuticals Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Nanoscope Therapeutics Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Oak bay Biosciences Ltd, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by ProQR Therapeutics NV, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Ray Therapeutics Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by ReVision Therapeutics Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Saliogen Therapeutics Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Shape Therapeutics Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Spark Therapeutics Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Splice Bio SL, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Stargazer Pharmaceuticals Inc, 2022
Juvenile Macular Degeneration (Stargardt Disease) - Dormant Projects, 2022